PROSTATE, LUNG, COLORECTAL, & OVARIAN CANCER SCREENING

前列腺癌、肺癌、结肠直肠癌和卵巢癌筛查试验（PLCO） 旨在确定60-74岁的筛选者在进入时是否： a. 在女性和男性中（1）采用乙状结肠镜检查进行筛查（60 cm乙状结肠镜）可以降低结肠直肠癌的死亡率;以及，（2） 胸部x光检查可降低肺癌死亡率。 B.男性（1）直肠指检加血清筛查 前列腺特异性抗原（PSA）可以降低前列腺疾病的死亡率。 癌症; C.在女性中（1例）进行盆腔检查加CA 125筛查， 经阴道超声可以降低卵巢癌的死亡率; 承包商应建立研究协调和数据管理 中心（CC）的PLCO癌症筛查试验，以开发和维护 生物医学数据管理所需的系统和程序， 协调、统计分析和报告撰写。 CC在其 协调工作充当筛查中心、 中央血液检测机构（LAB）、研究顾问和国家 癌症研究所项目官员。

The Prostate, Lung, Colon-rectum and Ovary Cancer Screening Trial (PLCO) is designed to determine in screenees aged 60-74 years at entry whether: a. In females and males (1) screening with flexible sigmoidoscopy (60 cm sigmoidoscope) can reduce mortality from colo-rectal cancer; and, (2) screening with chest x-ray can reduce mortality from lung cancer. b. In males (1) screening with digital rectal examination plus serum prostate-specific antigen (PSA) can reduce mortality from prostate cancer; C. In females (1) screening with pelvic examination plus CA 125 and transvaginal ultrasound can reduce mortality from ovarian cancer; The Contractor shall establish a Study Coordinating and Data Management Center (CC) for the PLCO Cancer Screening Trial to develop and maintain systems and procedures needed for biomedical data management, study coordination, statistical analysis, and report writing. The CC in its coordination efforts acts as a liaison between the Screening Centers, the Central Blood Testing Facility (LAB), study consultants, and the National Cancer Institute Project Officers.